Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Clin Apher ; 30(4): 217-23, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-25346275

RESUMO

BACKGROUND: In patients suffering from dilated cardiomyopathy (DCM), immunoadsorption with subsequent IgG substitution (IA/IgG) leads to an acute and prolonged improvement of hemodynamics and heart failure symptoms. However, some patients receiving IA/IgG experience recurrence of heart failure after an initial benefit. The aim of this study was to investigate whether a second IA/IgG treatment episode improves left ventricular systolic function and further mitigates heart failure symptoms in these patients. METHODS: We retrospectively analyzed 15 DCM patients who experienced a significant improvement of LVEF (≥ 5% absolute or ≥ 20% relative) and heart failure symptoms (≥ 1 NYHA functional class) but a subsequent deterioration (decline in LVEF ≥ 5% absolute or ≥ 20% relative and NYHA worsening ≥1 class) after the first IA/IgG. These patients underwent a second IA/IgG treatment 41.7 ± 27.4 months after the first cycle. Follow up data were acquired 3-6 months after both IA/IgG treatments. RESULTS: The first IA/IgG induced an improvement of LVEF from 33 ± 6.4% to 43.2 ± 7.9% (P < 0.001) and of mean NYHA functional class from 2.9 ± 0.26 to 1.8 ± 0.56 (P < 0.001). The second treatment was associated with a significant improvement in LVEF (from 29.7 ± 4.6% to 34.9 ± 8.3%, P = 0.013) and NYHA functional class (2.87 ± 0.64 to 2.33 ± 0.72; P = 0.02). This improvement was less pronounced compared to the first treatment with respect to both, LVEF (P = 0.09) and NYHA improvement (P = 0.04). CONCLUSION: In DCM patients, who experience a significant improvement of LVEF and heart failure symptoms after IA/IgG but a subsequent relapse during follow up, repeated IA/IgG may be considered.


Assuntos
Cardiomiopatia Dilatada/complicações , Cardiomiopatia Dilatada/terapia , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca/terapia , Imunoglobulina G/química , Idoso , Biópsia , Cardiomiopatia Dilatada/imunologia , Ecocardiografia , Ergometria , Teste de Esforço , Feminino , Insuficiência Cardíaca/imunologia , Testes de Função Cardíaca , Hemodinâmica , Humanos , Imunoglobulina G/imunologia , Técnicas de Imunoadsorção , Masculino , Pessoa de Meia-Idade , Recidiva , Estudos Retrospectivos , Espirometria , Volume Sistólico , Fatores de Tempo , Função Ventricular Esquerda
2.
Respirology ; 18(1): 170-8, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23279785

RESUMO

BACKGROUND AND OBJECTIVE: The assessment of static lung volumes and airway resistance is a frequently performed diagnostic procedure and considered as an important tool in medical surveillance to detect pulmonary diseases. The objectives of the study are to establish reference equations for body plethysmographic parameters in a representative adult population across a wide age range and to compare the normative values from this sample with previous ones. METHODS: Body plethysmography was applied in 1809 participants (885 males) of a cross-sectional, population-based survey (Study of Health in Pomerania). Individuals with cardiopulmonary disorders and/or a pack-year smoking history >10 years and participants with a body mass index >30 kg/m(2) were excluded. In total, 686 healthy individuals (275 males) aged 25-85 years were assessed. RESULTS: Prediction equations for both genders were established by quantile regression analysis taking into account the influence of age, height and weight. CONCLUSIONS: The study provides a novel set of prediction equations for static lung volumes and airway resistance obtained using body plethysmography. Compared with our findings, existing equations underestimated some normal values. The results emphasize the need for up-to-date reference equations.


Assuntos
Resistência das Vias Respiratórias/fisiologia , Medidas de Volume Pulmonar/métodos , Pulmão/fisiopatologia , Pletismografia Total/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valores de Referência , Espirometria
3.
Cells ; 11(24)2022 12 08.
Artigo em Inglês | MEDLINE | ID: mdl-36552736

RESUMO

The evolutionary conserved NEAT1-MALAT1 gene cluster generates large noncoding transcripts remaining nuclear, while tRNA-like transcripts (mascRNA, menRNA) enzymatically generated from these precursors translocate to the cytosol. Whereas functions have been assigned to the nuclear transcripts, data on biological functions of the small cytosolic transcripts are sparse. We previously found NEAT1-/- and MALAT1-/- mice to display massive atherosclerosis and vascular inflammation. Here, employing selective targeted disruption of menRNA or mascRNA, we investigate the tRNA-like molecules as critical components of innate immunity. CRISPR-generated human ΔmascRNA and ΔmenRNA monocytes/macrophages display defective innate immune sensing, loss of cytokine control, imbalance of growth/angiogenic factor expression impacting upon angiogenesis, and altered cell-cell interaction systems. Antiviral response, foam cell formation/oxLDL uptake, and M1/M2 polarization are defective in ΔmascRNA/ΔmenRNA macrophages, defining first biological functions of menRNA and describing new functions of mascRNA. menRNA and mascRNA represent novel components of innate immunity arising from the noncoding genome. They appear as prototypes of a new class of noncoding RNAs distinct from others (miRNAs, siRNAs) by biosynthetic pathway and intracellular kinetics. Their NEAT1-MALAT1 region of origin appears as archetype of a functionally highly integrated RNA processing system.


Assuntos
Imunidade Inata , Macrófagos , RNA Longo não Codificante , RNA de Transferência , Humanos , Genômica , Imunidade Inata/genética , Imunidade Inata/imunologia , Macrófagos/imunologia , RNA Longo não Codificante/genética , RNA Longo não Codificante/imunologia , RNA de Transferência/genética , RNA de Transferência/imunologia
4.
Pharmacotherapy ; 41(2): 198-204, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-33465818

RESUMO

STUDY OBJECTIVE: Long-term intake of proton pump inhibitors (PPIs) might increase the risk of cardiovascular events. One suggested mechanism is that PPIs inhibit the enzyme dimethylarginine dimethylaminohydrolase (DDAH) and thereby block the degradation of endothelial asymmetrical dimethylarginine (ADMA). Excess ADMA in turn leads to impaired endothelial nitric oxide (NO) generation. So far, this mechanism has only been established in human cell cultures. Previous studies that examined this pathway in human populations measured circulating ADMA and found no association with PPI use and excess plasma ADMA. But in a recent study, plasma ADMA was not correlated with intracellular ADMA. We therefore focused on changes in plasma citrulline as an indicator for potential DDAH inhibition. DESIGN: We analyzed the association between regular daily PPI intake and flow-mediated dilation (FMD) of the brachial artery as well as plasma concentrations of citrulline, arginine, ADMA, and symmetric dimethylarginine using inverse probability weighting to adjust for confounding and censoring. DATA SOURCE: Data of 1298 participants from two independent cohorts of the population-based Study of Health in Pomerania were used. PATIENTS: Participants of the population-based Study of Health in Pomerania are a stratified random sample of the study region. INTERVENTION: Regular daily intake of PPIs. MEASUREMENTS: FMD of the brachial artery and plasma concentrations of citrulline, arginine, ADMA, and symmetric dimethylarginine. MAIN RESULTS: Eighty-seven participants (57.5% female) were regular daily users of PPIs. In the fully adjusted models, associations were identified for FMD and plasma citrulline concentrations. PPI users revealed a 0.99% (95% CI: -1.96 to -0.02) lower FMD and 3.03 µmol/L (95% CI: -4.96 to -1.10) lower plasma citrulline levels as compared to non-users. CONCLUSION: Our data provide evidence that long-term intake of PPIs might inhibit human DDAH activity, resulting in impaired endothelial NO production and reduced vascular function. In the long run, this might explain an increased risk for cardiovascular diseases associated with long-term PPI use.


Assuntos
Endotélio Vascular , Óxido Nítrico , Inibidores da Bomba de Prótons , Arginina , Citrulina , Estudos Transversais , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/fisiologia , Feminino , Humanos , Masculino , Óxido Nítrico/metabolismo , Inibidores da Bomba de Prótons/uso terapêutico
5.
Respir Med ; 125: 1-7, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-28340855

RESUMO

BACKGROUND: Vitamin D deficiency is discussed to be associated with lung health. While former studies focused on subjects suffering from pulmonary diseases, we aimed to investigate the association of 25-hydroxy vitamin D [25(OH)D] with lung function in the general population and examined whether mediating effects of inflammation, glycemic control or renal function exist. METHODS: 1404 participants from the Study of Health in Pomerania with pulmonary function testing assessed by expiratory volume in 1 s (FEV1), forced vital capacity (FVC), total lung capacity and Krogh index were used. Adjusted analysis of variance, linear regression models and mediation analyses were performed. RESULTS: Significant positive associations between 25(OH)D levels and FEV1, FVC and Krogh index were found. Mediator analyses revealed no mediating effect of inflammation (fibrinogen), glycemic control (HbA1c) or renal function (eGFR) on associations with FEV1 or FVC. With respect to Krogh-Index, the association to 25(OH)D was slightly mediated by fibrinogen with a proportion mediated of 9.7%. CONCLUSION: Significant positive associations of 25(OH)D with lung function were revealed in a general population. The proposed mediating effects of inflammation, glycemic control and renal function on these relations were not confirmed. Further studies examining the causality of the association between 25(OH)D and lung function are necessary.


Assuntos
Glicemia/análise , Inflamação/fisiopatologia , Pulmão/fisiopatologia , Testes de Função Respiratória/métodos , Deficiência de Vitamina D/fisiopatologia , Vitamina D/análogos & derivados , Adulto , Idoso , Glicemia/fisiologia , Estudos Transversais , Feminino , Fibrinogênio/metabolismo , Volume Expiratório Forçado/fisiologia , Taxa de Filtração Glomerular/fisiologia , Hemoglobinas Glicadas , Humanos , Masculino , Pessoa de Meia-Idade , Capacidade Pulmonar Total/fisiologia , Capacidade Vital/fisiologia , Vitamina D/sangue
6.
Dtsch Arztebl Int ; 113(3): 40, 2016 Jan 22.
Artigo em Inglês | MEDLINE | ID: mdl-26857515
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA